<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="42702">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02550431</url>
  </required_header>
  <id_info>
    <org_study_id>15-1215</org_study_id>
    <secondary_id>UL1TR001082</secondary_id>
    <nct_id>NCT02550431</nct_id>
  </id_info>
  <brief_title>Trans Health: Evaluation of Markers of Cardio-metabolic Health and Well-being in Transgender Youth</brief_title>
  <official_title>Trans Health: Evaluation of Markers of Cardio-metabolic Health and Well-being in Transgender Youth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study plans to learn more about puberty blockers and cross (testosterone and
      estradiol). There is not much known about how these medications affect hormone levels, heart
      health and overall general health in young transgender individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study plans to learn more about puberty blockers and cross (testosterone and
      estradiol). There is not much known about how these medications affect hormone levels, heart
      health and overall general health in young transgender individuals.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Reproductive hormone concentrations in transgender youth on cross-sex hormones and/or puberty blockers and compared to age-, natal sex- and body mass index (BMI)-matched controls.</measure>
    <time_frame>at enrollment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Markers of cardiometabolic risk in transgender youth on cross-sex hormones and/or puberty blockers and compared to age-, natal sex- and BMI-matched controls</measure>
    <time_frame>at enrollment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Body composition as measured by Dual-energy X-ray absorptiometry (DEXA) in transgender youth compared to age- and BMI-matched controls of both sexes.</measure>
    <time_frame>at enrollment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Data on quality of life as measured by the Pediatric Quality of Life Inventory (PedsQL) compared to published norms</measure>
    <time_frame>at enrollment</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Transgendered Persons</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Transgender youth ages 9 to 21 years of age who have been on a Gonadotropin-releasing
        hormone (GnRH) agonist or cross-sex hormones for at least three months
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Followed in Endocrinology Clinic or Adolescent Medicine Clinic at Children's Hospital
             Colorado

          -  Between age 9 and 21 years (inclusive)

          -  Identifies as transgender

          -  Has been on pubertal blockade or cross-sex hormones for at least three months.

        Exclusion Criteria:

          -  Known diabetes

          -  Presence of significant medical or psychiatric comorbidities

          -  Using hormones not prescribed by a physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalie J Nokoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natalie J Nokoff, MD</last_name>
    <phone>720-777-3607</phone>
    <email>Natalie.Nokoff@childrenscolorado.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Nokoff, MD</last_name>
      <phone>720-777-3607</phone>
      <email>Natalie.Nokoff@childrenscolorado.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 25, 2016</lastchanged_date>
  <firstreceived_date>September 11, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
